Literature DB >> 29921134

The effect of combined therapy for treatment of monotherapy-resistant PDA in preterm infants.

Sadık Yurttutan1, Aydın Bozkaya1, Füheda Hüdayioglu2, Mehmet Yekta Oncel3.   

Abstract

Objective: Hemodynamically significant PDA (hsPDA) is one of the most common problems in preterm infants. This study was conducted to investigate the effect of combined pharmacological (paracetamol + ibuprofen) therapy on monotherapy-resistant hsPDA in infants. Subject and methods: The study included infants with persistent hsPDA, unresponsive to monotherapy. Combined treatment (paracetamol + ibuprofen) was started as paracetamol at a dose of 15 mg/kg every 6 hours for 5 days, and ibuprofen at an initial dose of 10 mg/kg followed by 5 mg/kg at 24 and 48 hours. Echocardiographic evaluation was performed at 2 days after the end of treatment. If hsPDA persisted after the combined treatment, a surgical PDA ligation was considered.
Results: A total of 12 infants were enrolled and 9 infants (75%) with monotherapy-resistant PDA were successfully treated with combined therapy. In three patients, no response was obtained to the combined treatment so surgical ligation was applied. Conclusions: Combined therapy may be a useful treatment option for monotherapy-resistant hsPDA in preterm infants. Before surgical ligations, this combined therapy option should be considered.

Entities:  

Keywords:  Paracetamol; combined therapy; ibuprofen; patent ductus arteriosus; preterms

Year:  2018        PMID: 29921134     DOI: 10.1080/14767058.2018.1481043

Source DB:  PubMed          Journal:  J Matern Fetal Neonatal Med        ISSN: 1476-4954


  7 in total

Review 1.  Different approaches for patent ductus arteriosus in premature infants using acetaminophen.

Authors:  Aimann Surak; Amish Jain; Abbas Hyderi
Journal:  World J Pediatr       Date:  2022-03-06       Impact factor: 2.764

2.  Dual Therapy vs. Monotherapy for the Patent Ductus Arteriosus: A Systematic Review.

Authors:  Cathy Hammerman; Alona Bin-Nun; Haytham Abdaljalil; Itamar Nitzan; Yair Kasirer; Rawan Abu-Omar; Irina Schorrs; Francis Mimouni
Journal:  Pediatr Cardiol       Date:  2022-04-05       Impact factor: 1.655

Review 3.  Patent Ductus Arteriosus of the Preterm Infant.

Authors:  Shannon E G Hamrick; Hannes Sallmon; Allison T Rose; Diego Porras; Elaine L Shelton; Jeff Reese; Georg Hansmann
Journal:  Pediatrics       Date:  2020-11       Impact factor: 7.124

4.  Use of combination therapy with acetaminophen and ibuprofen for closure of the patent ductus arteriosus in preterm neonates.

Authors:  Susan Kimani; Aimann Surak; Michael Miller; Soume Bhattacharya
Journal:  Paediatr Child Health       Date:  2020-05-21       Impact factor: 2.253

5.  Selective Treatment of PDA in High-Risk VLBW Infants With Birth Weight ≤800 g or <27 Weeks and Short-Term Outcome: A Cohort Study.

Authors:  Thowfique Ibrahim; Abdul Alim Abdul Haium; Sarah Jane Tapawan; Rowena Dela Puerta; John C Allen; Suresh Chandran; Mei Chien Chua; Victor Samuel Rajadurai
Journal:  Front Pediatr       Date:  2021-01-28       Impact factor: 3.418

Review 6.  Management of Patent Ductus Arteriosus in Premature Infants in 2020.

Authors:  Sarah Parkerson; Ranjit Philip; Ajay Talati; Shyam Sathanandam
Journal:  Front Pediatr       Date:  2021-02-11       Impact factor: 3.418

7.  An Update on Patent Ductus Arteriosus and What is Coming Next.

Authors:  Ömer Erdeve; Emel Okulu; Yogen Singh; Richard Sindelar; Mehmet Yekta Oncel; Gianluca Terrin; Giovanni Boscarino; Ali Bülbül; Hannes Sallmon; Begüm Atasay; Fahri Ovalı; Ronald I Clyman
Journal:  Turk Arch Pediatr       Date:  2022-03
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.